Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of the anti-PD-L1 antibody CS1001 paired with PARP inhibitor IMP4297 as a combination therapy for patients with advanced solid tumors

Next Previous
Trial Profile

A clinical study of the anti-PD-L1 antibody CS1001 paired with PARP inhibitor IMP4297 as a combination therapy for patients with advanced solid tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Senaparib (Primary) ; Sugemalimab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 13 Feb 2019 New trial record
  • 07 Feb 2019 According to a CStone Pharmaceuticals media release, Investigational New Drug (IND) filing has been accepted by the National Medical Products Administration (NMPA) for this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top